Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunocore Holdings plcIMCR · Entity 4544 | HEAD OF R&D | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunocore Holdings plc
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,859 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-17 · Exercise / conversion · Acquired 11,824 · Balance 11,824 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Row 2 · 2026-02-18 · Sale · Disposed 5,965 · Balance 5,859 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 35,473 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Exercise / conversion · Disposed 11,824 · Balance 35,473 F4: Each RSU represents a contingent right to receive one Ordinary Share. F5: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Each RSU represents a contingent right to receive one Ordinary Share.
F5: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 4,448 | $69.45 | $308,913.60 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,490 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.835 to $69.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 54,938 | $17.46 | $959,217.48 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 28,553 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · derivative · entry 9 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,237 Underlying: Ordinary Shares · 28,553 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F8 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 2,037 | $71.31 | $145,258.47 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.09 to $71.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 26,516 | $70.60 | $1,872,029.60 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,037 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.09 to $71.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 28,553 | $17.46 | $498,535.38 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 111,244 | $0.00 Strike: $70.50 | $0.00 |
DisclosureSEC source: 0001415889-24-004591 · form4-02212024_040222.xml · derivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,244 Underlying: Ordinary Shares · 111,244 shares Expires 2034-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.